Imunon Price To Book vs. Total Debt

IMNN Stock  USD 0.81  0.12  17.39%   
Considering Imunon's profitability and operating efficiency indicators, Imunon Inc may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Imunon's ability to earn profits and add value for shareholders. As of the 24th of November 2024, Price To Sales Ratio is likely to drop to 21.07. In addition to that, Days Sales Outstanding is likely to drop to 86.81. At this time, Imunon's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 24th of November 2024, Total Other Income Expense Net is likely to grow to about 246.8 K, while Operating Income is likely to drop (22.1 M).
For Imunon profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Imunon to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Imunon Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Imunon's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Imunon Inc over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.91)
Revenue Per Share
0.014
Return On Assets
(0.67)
Return On Equity
(1.48)
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Imunon Inc Total Debt vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Imunon's current stock value. Our valuation model uses many indicators to compare Imunon value to that of its competitors to determine the firm's financial worth.
Imunon Inc is rated below average in price to book category among its peers. It is rated below average in total debt category among its peers making up about  1,130,314  of Total Debt per Price To Book. As of the 24th of November 2024, Total Debt To Capitalization is likely to drop to 0.1. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Imunon's earnings, one of the primary drivers of an investment's value.

Imunon Total Debt vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Imunon

P/B

 = 

MV Per Share

BV Per Share

 = 
1.44 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Imunon

Total Debt

 = 

Bonds

+

Notes

 = 
1.62 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Imunon Total Debt vs Competition

Imunon Inc is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 84.2 Million. Imunon claims roughly 1.62 Million in total debt contributing just under 2% to equities under Health Care industry.
Total debt  Capitalization  Workforce  Revenue  Valuation

Imunon Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Imunon, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Imunon will eventually generate negative long term returns. The profitability progress is the general direction of Imunon's change in net profit over the period of time. It can combine multiple indicators of Imunon, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income60.8 K63.8 K
Operating Income-21 M-22.1 M
Income Before Tax-20.8 M-21.8 M
Total Other Income Expense Net235.1 K246.8 K
Net Loss-19.5 M-20.5 M
Income Tax Expense-1.3 M-1.2 M
Net Interest Income850.4 K892.9 K
Interest Income1.2 M1.3 M
Net Loss-27.9 M-29.3 M
Net Loss-32.3 M-33.9 M
Change To Netincome12.2 M12.9 M
Net Loss(2.16)(2.27)
Income Quality 0.97  0.58 
Net Income Per E B T 0.94  0.99 

Imunon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Imunon. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Imunon position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Imunon's important profitability drivers and their relationship over time.

Use Imunon in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.

Imunon Pair Trading

Imunon Inc Pair Trading Analysis

The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Imunon position

In addition to having Imunon in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Municipals ETFs Thematic Idea Now

Municipals ETFs
Municipals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Municipals ETFs theme has 109 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Municipals ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock:
Check out Risk vs Return Analysis.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
To fully project Imunon's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Imunon Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Imunon's income statement, its balance sheet, and the statement of cash flows.
Potential Imunon investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Imunon investors may work on each financial statement separately, they are all related. The changes in Imunon's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Imunon's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.